Dabigatran Reversal with Idarucizumab
- 26 October 2017
- journal article
- letter
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 377 (17), 1690-1692
- https://doi.org/10.1056/nejmc1711337
Abstract
Correspondence from The New England Journal of Medicine — Dabigatran Reversal with IdarucizumabKeywords
This publication has 9 references indexed in Scilit:
- Emergency Coagulation Assessment During Treatment With Direct Oral AnticoagulantsStroke, 2017
- Idarucizumab for Dabigatran Reversal — Full Cohort AnalysisThe New England Journal of Medicine, 2017
- Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany – A national case collectionInternational Journal of Stroke, 2017
- Laboratory Assessment of the Anticoagulant Activity of Direct Oral AnticoagulantsSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2017
- Managing reversal of direct oral anticoagulants in emergency situationsThrombosis and Haemostasis, 2016
- Idarucizumab for Dabigatran ReversalThe New England Journal of Medicine, 2015
- Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agentsJournal of Thrombosis and Thrombolysis, 2015
- Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatranThrombosis and Haemostasis, 2015
- Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With the Direct Thrombin Inhibitor DabigatranStroke, 2011